549 related articles for article (PubMed ID: 29978293)
1. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
Saeheng T; Na-Bangchang K; Karbwang J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
[TBL] [Abstract][Full Text] [Related]
2. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
3. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.
Block M
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):743-56. PubMed ID: 25940026
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
Rioux N; Waters NJ
Drug Metab Dispos; 2016 Jul; 44(7):934-43. PubMed ID: 26936973
[TBL] [Abstract][Full Text] [Related]
7. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs.
Wang X; Chen F; Guo N; Gu Z; Lin H; Xiang X; Shi Y; Han B
Cancer Chemother Pharmacol; 2023 Oct; 92(4):253-270. PubMed ID: 37466731
[TBL] [Abstract][Full Text] [Related]
8. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
9. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
Min JS; Bae SK
Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.
Huang W; Nakano M; Sager J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2017 Nov; 45(11):1156-1165. PubMed ID: 28860113
[TBL] [Abstract][Full Text] [Related]
11. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.
Björkman S
J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):285-307. PubMed ID: 14650375
[TBL] [Abstract][Full Text] [Related]
12. Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling.
Chou WC; Lin Z
Toxicol Sci; 2023 Jan; 191(1):1-14. PubMed ID: 36156156
[TBL] [Abstract][Full Text] [Related]
13. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
14. Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds.
Mao J; Ma F; Yu J; Bruyn T; Ning M; Bowman C; Chen Y
Biopharm Drug Dispos; 2023 Aug; 44(4):315-334. PubMed ID: 37160730
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
[TBL] [Abstract][Full Text] [Related]
16. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
17. Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.
Horiuchi K; Ohnishi S; Matsuzaki T; Funaki S; Watanabe A; Mizutare T; Matsumoto S; Nezasa KI; Hasegawa H
J Pharm Sci; 2018 May; 107(5):1443-1453. PubMed ID: 29331382
[TBL] [Abstract][Full Text] [Related]
18. In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools.
Krstevska A; Đuriš J; Ibrić S; Cvijić S
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678737
[TBL] [Abstract][Full Text] [Related]
19. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents.
Mahmood I; Tegenge MA
J Clin Pharmacol; 2019 Feb; 59(2):189-197. PubMed ID: 30192373
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview.
Perry C; Davis G; Conner TM; Zhang T
Curr Pharmacol Rep; 2020; 6(3):71-84. PubMed ID: 32399388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]